The Impact of Serum C-peptide Level on Bone Mineral Density in Postmenopausal Type 2 Diabetic Women. Bone mineral density and serum c-peptide.

Main Article Content

Berna İmge Aydoğan
Adile Begüm Bahçecioğlu Mutlu
Çağlar Keskin
Funda Seher Özalp Ateş
Sevim Güllü

Abstract

Objective: Recent studies suggested that c-peptide had biological activity on bone metabolism. We aimed to evaluate the impact of c-peptide level on bone mineral density (BMD) in postmenopausal type 2 diabetic women.


Methods: Thirty-five insulin naïve type 2 diabetic postmenopausal women were included in our prospective cohort study. Fasting and random c-peptide, parathyroid hormone (PTH), vitamin D, insulin, alkaline phosphatase level (ALP) levels and BMD were evaluated.


Results: The mean age of patients was 61.8±8.56 years. The mean fasting c-peptide, random c-peptide and insulin levels were 3.0±1.24, 7.7±3.7 and 13.9±11.2 µIU/ml, respectively. The mean femoral neck (FN-BMD) and total lumbar spine bone mineral density (L-BMD) were 0.787±0.127 and 0.919±0.122 g/cm2, respectively. C-peptide level was associated with total hip BMD (p<0.05) but this relation disappeared after regression analysis adjusted for confounders. A negative correlation between PTH level and FN-BMD was found (p=0.01). Total hip BMD and L-BMD were negatively correlated with age (p=0.01 and p=0.02, respectively). A positive association between DPP4 inhibitor treatment and total hip BMD was observed (p=0.03).


Conclusions: We observed a positive association between total hip BMD and serum c-peptide level. However, this relationship disappeared in multiple linear regression analysis. Further studies are necessary to evaluate the impact of c-peptide level on the risk of osteoporosis in T2DM.

Downloads

Download data is not yet available.

Article Details

How to Cite
AydoğanB. İmge, Bahçecioğlu MutluA. B., Keskin Çağlar, Özalp AteşF. S., & GüllüS. (2019). The Impact of Serum C-peptide Level on Bone Mineral Density in Postmenopausal Type 2 Diabetic Women. Medical Science and Discovery, 6(9), 166-172. https://doi.org/10.36472/msd.v6i9.274
Section
Research Article

References

1. Nevitt MC, Ettinger B, Black DM, Stone K, Jamal SA, Ensrud K, et al. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Annals of internal medicine. 1998 May 15;128(10):793-800. PubMed PMID: 9599190.
2. Gold DT. The nonskeletal consequences of osteoporotic fractures. Psychologic and social outcomes. Rheumatic diseases clinics of North America. 2001 Feb;27(1):255-62. PubMed PMID: 11285999.
3. Cooper C, Atkinson EJ, Jacobsen SJ, O'Fallon WM, Melton LJ, 3rd. Population-based study of survival after osteoporotic fractures. American journal of epidemiology. 1993 May 1;137(9):1001-5. PubMed PMID: 8317445.
4. Magaziner J, Lydick E, Hawkes W, Fox KM, Zimmerman SI, Epstein RS, et al. Excess mortality attributable to hip fracture in white women aged 70 years and older. American journal of public health. 1997 Oct;87(10):1630-6. PubMed PMID: 9357344. Pubmed Central PMCID: 1381125.
5. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2007 Apr;18(4):427-44. PubMed PMID: 17068657.
6. Janghorbani M, Feskanich D, Willett WC, Hu F. Prospective study of diabetes and risk of hip fracture: the Nurses' Health Study. Diabetes care. 2006 Jul;29(7):1573-8. PubMed PMID: 16801581.
7. Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, et al. Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. The Journal of clinical endocrinology and metabolism. 2006 Sep;91(9):3404-10. PubMed PMID: 16804043.
8. Chen FP, Kuo SF, Lin YC, Fan CM, Chen JF. Status of bone strength and factors associated with vertebral fracture in postmenopausal women with type 2 diabetes. Menopause. 2018 Aug 20. PubMed PMID: 30130285.
9. Rakic V, Davis WA, Chubb SA, Islam FM, Prince RL, Davis TM. Bone mineral density and its determinants in diabetes: the Fremantle Diabetes Study. Diabetologia. 2006 May;49(5):863-71. PubMed PMID: 16518589.
10. Reid IR, Evans MC, Cooper GJ, Ames RW, Stapleton J. Circulating insulin levels are related to bone density in normal postmenopausal women. The American journal of physiology. 1993 Oct;265(4 Pt 1):E655-9. PubMed PMID: 8238341.
11. Shanbhogue VV, Finkelstein JS, Bouxsein ML, Yu EW. Association Between Insulin Resistance and Bone Structure in Nondiabetic Postmenopausal Women. The Journal of clinical endocrinology and metabolism. 2016 Aug;101(8):3114-22. PubMed PMID: 27243136. Pubmed Central PMCID: 4971339.
12. Abrahamsen B, Rohold A, Henriksen JE, Beck-Nielsen H. Correlations between insulin sensitivity and bone mineral density in non-diabetic men. Diabetic medicine : a journal of the British Diabetic Association. 2000 Feb;17(2):124-9. PubMed PMID: 10746482.
13. Thrailkill KM, Lumpkin CK, Jr., Bunn RC, Kemp SF, Fowlkes JL. Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. American journal of physiology Endocrinology and metabolism. 2005 Nov;289(5):E735-45. PubMed PMID: 16215165. Pubmed Central PMCID: 2387001.
14. Roy B. Biomolecular basis of the role of diabetes mellitus in osteoporosis and bone fractures. World journal of diabetes. 2013 Aug 15;4(4):101-13. PubMed PMID: 23961320. Pubmed Central PMCID: 3746082.
15. Ho-Pham LT, Chau PMN, Do AT, Nguyen HC, Nguyen TV. Type 2 diabetes is associated with higher trabecular bone density but lower cortical bone density: the Vietnam Osteoporosis Study. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2018 Sep;29(9):2059-67. PubMed PMID: 29967929.
16. Nilsson AG, Sundh D, Johansson L, Nilsson M, Mellstrom D, Rudang R, et al. Type 2 Diabetes Mellitus Is Associated With Better Bone Microarchitecture But Lower Bone Material Strength and Poorer Physical Function in Elderly Women: A Population-Based Study. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2017 May;32(5):1062-71. PubMed PMID: 27943408.
17. Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes. 1992 Mar;41(3):368-77. PubMed PMID: 1551497.
18. Ciresi A, Ciccio F, Radellini S, Giordano C. Utility of C-peptide for a reliable estimate of insulin secretion in children with growth hormone deficiency. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 2016 Aug;29:71-7. PubMed PMID: 27235725.
19. Al-Rasheed NM, Meakin F, Royal EL, Lewington AJ, Brown J, Willars GB, et al. Potent activation of multiple signalling pathways by C-peptide in opossum kidney proximal tubular cells. Diabetologia. 2004 Jun;47(6):987-97. PubMed PMID: 15164168.
20. Wahren J, Ekberg K, Johansson J, Henriksson M, Pramanik A, Johansson BL, et al. Role of C-peptide in human physiology. American journal of physiology Endocrinology and metabolism. 2000 May;278(5):E759-68. PubMed PMID: 10780930.
21. Lopez-Ibarra PJ, Pastor MM, Escobar-Jimenez F, Pardo MD, Gonzalez AG, Luna JD, et al. Bone mineral density at time of clinical diagnosis of adult-onset type 1 diabetes mellitus. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2001 Sep-Oct;7(5):346-51. PubMed PMID: 11585369.
22. Yamaguchi T, Kanazawa I, Yamamoto M, Kurioka S, Yamauchi M, Yano S, et al. Associations between components of the metabolic syndrome versus bone mineral density and vertebral fractures in patients with type 2 diabetes. Bone. 2009 Aug;45(2):174-9. PubMed PMID: 19446053.
23. Montalcini T, Gallotti P, Coppola A, Zambianchi V, Fodaro M, Galliera E, et al. Association between low C-peptide and low lumbar bone mineral density in postmenopausal women without diabetes. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2015 May;26(5):1639-46. PubMed PMID: 25616509. Pubmed Central PMCID: 4428888.
24. Li Y, Liu H, Sato Y. The association between the serum C-peptide level and bone mineral density. PloS one. 2013;8(12):e83107. PubMed PMID: 24358252. Pubmed Central PMCID: 3865098.
25. Russo C, Lazzaro V, Gazzaruso C, Maurotti S, Ferro Y, Pingitore P, et al. Proinsulin C-peptide modulates the expression of ERK1/2, type I collagen and RANKL in human osteoblast-like cells (Saos-2). Molecular and cellular endocrinology. 2017 Feb 15;442:134-41. PubMed PMID: 28007656.
26. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 1994 Nov;4(6):368-81. PubMed PMID: 7696835.
27. Wahren J, Kallas A, Sima AA. The clinical potential of C-peptide replacement in type 1 diabetes. Diabetes. 2012 Apr;61(4):761-72. PubMed PMID: 22442295. Pubmed Central PMCID: 3314360.
28. Gubitosi-Klug RA, Group DER. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions. Diabetes care. 2014;37(1):44-9. PubMed PMID: 24356597. Pubmed Central PMCID: 3867991.
29. Lachin JM, McGee P, Palmer JP, Group DER. Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes. 2014 Feb;63(2):739-48. PubMed PMID: 24089509. Pubmed Central PMCID: 3900540.
30. Francis MJ, Lees RL, Trujillo E, Martin-Vasallo P, Heersche JN, Mobasheri A. ATPase pumps in osteoclasts and osteoblasts. The international journal of biochemistry & cell biology. 2002 May;34(5):459-76. PubMed PMID: 11906818.
31. Ohtomo Y, Bergman T, Johansson BL, Jornvall H, Wahren J. Differential effects of proinsulin C-peptide fragments on Na+, K+-ATPase activity of renal tubule segments. Diabetologia. 1998 Mar;41(3):287-91. PubMed PMID: 9541168.
32. Kitamura T, Kimura K, Jung BD, Makondo K, Okamoto S, Canas X, et al. Proinsulin C-peptide rapidly stimulates mitogen-activated protein kinases in Swiss 3T3 fibroblasts: requirement of protein kinase C, phosphoinositide 3-kinase and pertussis toxin-sensitive G-protein. The Biochemical journal. 2001 Apr 1;355(Pt 1):123-9. PubMed PMID: 11256956. Pubmed Central PMCID: 1221719.
33. Saito M, Marumo K. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2010 Feb;21(2):195-214. PubMed PMID: 19760059.
34. Kujath AS, Quinn L, Elliott ME, LeCaire TJ, Binkley N, Molino AR, et al. Different health behaviours and clinical factors associated with bone mineral density and bone turnover in premenopausal women with and without type 1 diabetes. Diabetes/metabolism research and reviews. 2015 May;31(4):421-32. PubMed PMID: 25470722. Pubmed Central PMCID: 4406845.
35. Ferro Y, Russo C, Russo D, Gazzaruso C, Coppola A, Gallotti P, et al. Association between low C-peptide and fragility fractures in postmenopausal women without diabetes. Journal of endocrinological investigation. 2017 Oct;40(10):1091-8. PubMed PMID: 28401528.
36. Nuche-Berenguer B, Portal-Nunez S, Moreno P, Gonzalez N, Acitores A, Lopez-Herradon A, et al. Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor. Journal of cellular physiology. 2010 Nov;225(2):585-92. PubMed PMID: 20506394.
37. Zhong Q, Itokawa T, Sridhar S, Ding KH, Xie D, Kang B, et al. Effects of glucose-dependent insulinotropic peptide on osteoclast function. American journal of physiology Endocrinology and metabolism. 2007 Feb;292(2):E543-8. PubMed PMID: 17003233.
38. Lu N, Sun H, Yu J, Wang X, Liu D, Zhao L, et al. Glucagon-like peptide-1 receptor agonist Liraglutide has anabolic bone effects in ovariectomized rats without diabetes. PloS one. 2015;10(7):e0132744. PubMed PMID: 26177280. Pubmed Central PMCID: 4503456.
39. Iepsen EW, Lundgren JR, Hartmann B, Pedersen O, Hansen T, Jorgensen NR, et al. GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women. The Journal of clinical endocrinology and metabolism. 2015 Aug;100(8):2909-17. PubMed PMID: 26043228.
40. Monami M, Dicembrini I, Antenore A, Mannucci E. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes care. 2011 Nov;34(11):2474-6. PubMed PMID: 22025784. Pubmed Central PMCID: 3198283.